{"id":"W4318773806","doi":"10.1136/jitc-2022-006127","title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"EMD Serono; Ipsen; Universiteit Gent; Astellas Pharma; Eisai; G1 Therapeutics; Sanofi; Apollomics; Agios Pharmaceuticals; University of Texas Southwestern Medical Center; BeiGene; GlaxoSmithKline; Tizona Therapeutics; Les Laboratories Pierre Fabre; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; AstraZeneca; Novocure; MacroGenics; Celldex Therapeutics; Cilag; Puma Biotechnology; Regeneron Pharmaceuticals; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Celgene; PTC Therapeutics; Genentech; Aeglea BioTherapeutics; Amgen; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Internal medicine; Lung cancer; Metastatic melanoma; First line; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004248051,0.0003401087,0.0006842556,0.0003408655,0.0005313795,0.0000673406,0.0001555226,0.00009229415,0.0002841538],"category_scores_gemma":[0.00001859954,0.0002630843,0.0002598192,0.0004061419,0.0001121441,0.000240629,0.00002423938,0.0002155303,8.797103e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006412177,"about_ca_system_score_gemma":0.0005659518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005272491,"about_ca_topic_score_gemma":0.0006290249,"domain_scores_codex":[0.9978901,0.00002333999,0.0007757352,0.0003057832,0.0003886218,0.0006164819],"domain_scores_gemma":[0.9983826,0.0001153437,0.0007188666,0.0002323147,0.0004255341,0.0001253271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1357956,0.0008484611,0.5262635,0.005836526,0.005279087,0.000006705133,0.009907742,0.009627108,0.01011148,0.00003380215,0.009888788,0.2864012],"study_design_scores_gemma":[0.1902207,0.008783668,0.5147362,0.005909549,0.001916335,0.00003679586,0.00102733,0.04016334,0.01233575,0.0003435608,0.2228064,0.001720357],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9838194,0.01058523,0.0009719791,0.0003979054,0.001553681,0.002151332,0.000421287,0.00003548154,0.0000636534],"genre_scores_gemma":[0.9432225,0.04291683,0.005400174,0.0009551566,0.002033515,0.001097099,0.0001014375,0.000311169,0.003962127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2846808,"threshold_uncertainty_score":0.9999821,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04147329883353722,"score_gpt":0.3365720828331165,"score_spread":0.2950987839995792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}